eQcell Inc.

New clinical trial at the Ontario Veterinary College (OVC) using stem cells from eQcell to treat osteoarthritis in fetlock and carpal joints of horses. Previous studies have shown that horses are 3.4 times more likely to return to previous work compared with hyaluronic acid (HA) and that eQcell’s stem cells reduce structural damage within the joints. This study compares two different dosages of stem cells to Prostride® APS so a horse has 67% chance of receiving stem cells in the study. Veterinarian from OVC will drive to farms for treatment and assessment if the horse cannot be transported to OVC. Please contact Dr. Judith Koenig at [email protected] if you would like to learn more about the study and enrolment.

https://ovcclinicaltrials.uoguelph.ca/large-animal/
, , , , , , , , , .

All Active Large Animal Clinical Trials – OVC Clinical Trials Study Title: Do Activated Umbilical Cord Blood-Derived Mesenchymal Stromal Cells Treat Equine Fetlock and Carpal Osteoarthritis Effectively?

Thomas Koch, DVM, PhD
Founder, Chief Executive Officer & Chief Scientific Officer at eQcell Inc.

Congratulations to all the authors of this exciting case series published in JAVMA! https://lnkd.in/e24si2JB

This manuscript from Colorado State University reports on the effectiveness of eQcell's activated mesenchymal stem cells (MSCs) in treating bacterial infections, including those caused by antibiotic-resistant bacteria. This report is aligned with a case report from the Ontario Veterinary College published in March (https://lnkd.in/eFZKfU27), which reported the survival and full recovery of a foal with severe septic osteomyelitis following the addition of activated MSCs to the treatment protocol.

Use of these cells in cases with naturally occurring infections is based on foundational research from Colorado State University, conducted by Drs. Steve Dow, Lynn Pezzanite, and Laurie Goodrich, which has shown that activated MSCs are more effective at treating infections than non-activated cells. These earlier studies utilized fresh MSCs. These case reports confirm that eQcell's off-the-shelf, ready-to-use, frozen cells have a significant clinical impact in challenging real-life cases.

A key advantage of these activated MSCs over other emerging antimicrobial therapies, such as bacteriophage therapy, is their broad applicability; MSCs are largely bacterial species agnostic, making them particularly suitable for culture-negative infections or those involving multiple bacterial species. The ability of MSCs to secrete enzymes that break down biofilms aids in their effectiveness against resistant infections.
https://lnkd.in/epYCJfpY

, hashtag , hashtag , hashtag ,hashtag ,hashtag ,hashtag ,hashtag